Status: Available
Inhaled Treprostinil Expanded Access Program in Pulmonary Hypertension Associated With Interstitial Lung Disease
This is an Expanded Access Program (EAP) for eligible participants with Pulmonary Hypertension associated with Interstitial Lung Disease (PH-ILD) designed to provide access to Inhaled Treprostinil. Availability will depend on territory elegibility.
Trial details
Age: 18+Biological sex: AllType: Expanded AccessSponsor: Ferrer Internacional S.A.Updated: Oct 10, 2022
Eligibility criteria
Patient consent [+2]
Diagnosis of PAH or PH for reasons other than Group 3 PH-ILD [+2]